Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.

Base Genomics logo

Base Genomics joined the BioEscalator in March 2020 after meeting stringent gateway criteria set by the BioEscalator Management Board, who recognised the company’s high growth potential. In 6 months, they have grown from one lab space to two labs and an office with a third lab soon to be occupied. The BioEscalator has been able to support this rapid expansion by providing flexible space and serviced facilities.

Base Genomics was co-founded in 2018 by two Oxford academics Dr Yibin Liu and Dr Chunxiao Song from the Ludwig Institute and OSI’s Entrepreneur in Residence, Oliver Waterhouse, now CEO at Base. Their aim was to focus on developing a simple blood test to detect early-stage cancers.

The underlying DNA methylation detection technology, TAPS, capable long-read DNA sequencing, was developed at the Ludwig Institute for Cancer Research by Drs Liu and Song. Base Genomics’ leadership team is completed by Oxford alumna Dr Vincent Smith and Prof Anna Schuh, who is also Director of Molecular Diagnostics at the University’s Department of Oncology.

The full story can be viewed on the BioEscalator website

Similar stories

Professor Dame Sarah Gilbert delivers 44th Dimbleby Lecture

Professor Dame Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute & Nuffield Department of Clinical Medicine, delivered the 44th Richard Dimbleby Lecture, named after the late broadcaster, Richard Dimbleby.

Com-COV2 study supports flexible second dose options following Pfizer or Oxford/AstraZeneca jabs

Following up first doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines with second doses of the Moderna or Novavax jabs will generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Meta must do better - data from social media giant essential to mental health research

People are rightly sceptical about scientific discoveries made in secret or without scrutiny. And anyone claiming to have found a new planet with a toy telescope, would not be taken seriously. Recent leaks of internal Facebook research on the mental health of children and young people have caused a great stir on both sides of the Atlantic.

New Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease

GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Oxford researchers honoured by British Society for Immunology

Four researchers from the University of Oxford have been recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology, with the awards being announced at the recent British Society for Immunology Congress held in Edinburgh.

Medical Sciences researchers scoop 2021 Times Higher Education Awards

Coronavirus researchers from across Medical Sciences have been honoured at the 2021 Times Higher Education (THE) Awards.